1,721,090 research outputs found
Frequency and allelic association of common variants in the lipoprotein lipase gene in different etnhic groups. The Wansworth Heart & Stroke Study
No full textFrequency and allelic association of common variants in the lipoprotein lipase gene in different etnhic groups. The Wansworth Heart & Stroke Study
No full textEffect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
No full textWe examined whether the ACE gene insertion/deletion (I/D) polymorphism modulates renal disease progression in IDDM and how ACE inhibitors influence this relationship. The EURODIAB Controlled Trial of Lisinopril in IDDM is a multicenter randomized placebo-controlled trial in 530 nonhypertensive, mainly normoalbuminuric IDDM patients aged 20-59 years. Albumin excretion rate (AER) was measured every 6 months for 2 years. Genotype distribution was 15% II, 58% ID, and 27% DD. Between genotypes, there were no differences in baseline characteristics or in changes in blood pressure and glycemic control throughout the trial. There was a significant interaction between the II and DD genotype groups and treatment on change in AER (P = 0.05). Patients with the II genotype showed the fastest rate of AER progression on placebo but had an enhanced response to lisinopril. AER at 2 years (adjusted for baseline AER) was 51.3% lower on lisinopril than placebo in the II genotype patients (95% CI, 15.7 to 71.8; P = 0.01), 14.8% in the ID group (-7.8 to 32.7; P = 0.2), and 7.7% in the DD group (-36.6 to 37.6; P = 0.7). Absolute differences in AER between placebo and lisinopril at 2 years were 8.1, 1.7, and 0.8 microg/min in the II, ID, and DD groups, respectively. The significant beneficial effect of lisinopril on AER in the II group persisted when adjusted for center, blood pressure, and glycemic control, and also for diastolic blood pressure at 1 month into the study. Progression from normoalbuminuria to microalbuminuria (lisinopril versus placebo) was 0.27 (0.03-2.26; P = 0.2) in the II group, and 1.30 (0.33-5.17; P = 0.7) in the DD group (P = 0.6 for interaction). Knowledge of ACE genotype may be of value in determining the likely impact of ACE inhibitor treatment
Variable effects of the APOC3-482C>T variant on insulin, glucose and triglyceride concentrations in different ethnic groups
No full textLipoprotein Lipase Variants D9N and N291S are associated with Increased Plasma Triglyceride and Lower High-Density Lipoprotein Cholesterol concentrations. Studies in the Fasting and Postprandial States. The European Atherosclerosis Research Studies.
No full text
Lipoprotein Lipase Variants D9N and N291S are associated with Increased Plasma Triglyceride and Lower High-Density Lipoprotein Cholesterol concentrations. Studies in the Fasting and Postprandial States. The European Atherosclerosis Research Studies.
No full textMetformin for obesity in children and adolescents: a systematic review.
Full text linkOBJECTIVE: To summarize the efficacy of metformin in reducing BMI and cardiometabolic risk in obese children and adolescents without diabetes. RESEARCH DESIGN AND METHODS: We performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Double-blind RCTs of > or =6 months duration in obese subjects age < or =19 years without diabetes were included. Our primary outcomes of interest include changes in BMI and measures of insulin sensitivity. RESULTS: Five trials met inclusion criteria (n = 320 individuals). Compared with placebo, metformin reduced BMI by 1.42 kg/m(2) (95% CI 0.83-2.02) and homeostasis model assessment insulin of resistance (HOMA-IR) score by 2.01 (95% CI 0.75-3.26). CONCLUSIONS: Metformin appears to be moderately efficacious in reducing BMI and insulin resistance in hyperinsulinemic obese children and adolescents in the short term. Larger, longer-term studies in different populations are needed to establish its role in the treatment of overweight children
Variable effects of the APOC3-482C>T variant on insulin, glucose and triglyceride concentrations in different ethnic groups
No full textLipoprotein Lipase Variants D9N and N291S are associated with Increased Plasma Triglyceride and Lower High-Density Lipoprotein Cholesterol concentrations. Studies in the Fasting and Postprandial States. The European Atherosclerosis Research Studies.
No full text- …
